CLEVELAND, July 18, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second-quarter ended June 30, 2023 before the market opens on Thursday, August 3, 2023. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company’s operating highlights and financial results.
To participate in the live call, please dial 1-877-270-2148 if dialing-in from the United States, or 1-412-902-6510 if dialing-in from other locations. For direct connection to the conference call, participants are strongly encouraged to register in advance at this link. A live webcast of the conference call and accompanying materials may also be accessed via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health. A replay of the webcast will be available later in the day on August 3rd.
Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
Contacts | |
Jason Peterson | |
Vice President & Treasurer, Sotera Health | |
This email address is being protected from spambots. You need JavaScript enabled to view it. | |
Kristin Gibbs | |
Chief Marketing Officer, Sotera Health | |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$13.21 |
Daily Change: | -0.40 -2.94 |
Daily Volume: | 2,407,179 |
Market Cap: | US$3.740B |
November 05, 2024 September 04, 2024 August 05, 2024 May 30, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB